OBJECTIVES: Factors influencing allograft valve failure in adult patients are still under discussion. There is evidence in heart transplantation that gender mismatching may influence patient outcome. In case of aortic valve replacement with a homograft valve, gender matching is not performed routinely. The aim of this study was to investigate the impact of gender mismatch of human aortic homografts.
INTRODUCTION
Failure and calcification of human allografts have been attributed to graft-specific antibody responses [1] . However, so far this has not led to a recommendation to use gender-or blood group-matched allografts. High donor age, young patient age, homograft size mismatching and pulmonary homografts in the aortic position are suggested to be risk factors for valve failure [2] [3] [4] . Furthermore, implantation technique and sterilization technique also seem to have an impact on long-term valve function, whereas blood group incompatibility apparently does not [2, 5] .
There is evidence in heart transplantation that gender mismatching may influence patient outcome [6, 7] . Especially the combination of female donor and male recipient shows an increased risk for early and late mortality. Some authors assume size mismatch to be an important risk factor [8] . Other potential mechanisms that explain these findings are influence of minor histocompatibility antigen H-Y, different hormonal composition between sexes and other genetic differences [7, 9] .
If gender matching is not performed, preserved viability and antigenicity of homograft valves might influence graft durability and patient outcome due to similar mechanisms.
The aim of this study was to investigate the impact of gender mismatch of human aortic homografts on long-term outcome.
Primary diagnoses were aortic stenosis (42%, n = 147), aortic regurgitation (40%, n = 140) or mixed aortic valve disease (18%, n = 63). Degenerative valve disease was present in 80.8% (n = 283) and endocarditis in 19.1% (n = 67) of patients. Of the total, 38% (n = 133) of patients required additional surgical procedures: coronary artery bypass grafting (CABG), replacement of the ascending aorta (AAR) and/or mitral valve surgery (MVS).
Systemic hypertension and diabetes were defined by medical treatment of the patient. Twenty-one patients had a previous aortic valve replacement with mechanical prosthesis, tissue valve or allograft. The need for reoperation and echocardiographic valve failure were evaluated during follow-up. The preoperative patient profile is given in Table 1 .
Allograft data
All 350 homografts were obtained from our in-house homograft bank, established since the beginning of homograft surgery at our centre; 90.6% (n = 317) of valves were explanted from heartbeating donors (HBDs), mainly heart transplant recipients or rejected donor hearts, and 9.4% (n = 33) from cadaveric valve donors (non-HBDs).
Donor hearts were transported to the homograft bank in a sterile plastic container containing Medium199 (Biochrom AG, Berlin, Germany). Grafts were dissected and trimmed under sterile conditions as soon as possible and then either cryopreserved in liquid nitrogen (91.0%, n = 319) or stored as fresh wet valves in Medium199 at 4°C (9%, n = 31) until implantation. Sterilization with an antibiotic and antimycotic cocktail, containing Ciprofloxacin (3 mg/100 ml), Amicacin (2 mg/100 ml), Vancomycin (2 mg/100 ml), Metronidazol (2 mg/100 ml) and Amphotericin B (0.5 mg/100 ml), was carried out for valves from non-HBDs or in case of fresh wet storage. Cryopreserved valves were not routinely sterilized. Cryopreservation followed a standardized protocol: first the valves were placed into a cryoprotectant medium containing 60 ml Medium199 and 10% dimethylsulphoxide as crystallization protection (WAK-Chemie, Steinbach, Germany), then immediately controlled-rate frozen until a temperature of −150°C was attained. Contraindication for allograft use was: donor seropositive for human immunodeficiency virus or viral hepatitis, age >60 years, active endo-/myocarditis and time between death and harvest >24 h. Allograft data are reported in Table 2 .
Surgical technique
Aortic valve replacement was performed via median sternotomy, using standard cardiopulmonary bypass techniques and Bretschneider's solution (1500-2500 ml) in moderate or deep hypothermia, depending on the requirement of additional circulatory arrest. After intraoperative re-assessment of the anatomy, a sizematched homograft was thawed at 40°C and trimmed if necessary. Two implantation techniques as described earlier were used [10] : subcoronary implantation in 19.1% (n = 67) and mini-root replacement in 81.1% (n = 283) of cases. The surgical procedure was switched to the mini-root technique in 1995, due to two consecutive perioperative graft insufficiencies using the subcoronary technique. In male recipients, associated procedures were performed as follows: CABG in 8.8% (n = 17) for MM and 6.3% (n = 4) for MF, and MVS in 3.1% (n = 6) for MM and 3.1% (n = 2) for MF. AAR was done in 20.2% (n = 39) for MM and 17.1% (n = 11) for MF. In female recipients, CABG was performed in 10.9% (n = 5) for FF and 14.9% (n = 7) for FM, and MVS in 4.3% (n = 2) for FF and 4.3% (n = 2) for FM. AAR was done in 17.4% (n = 8) for FF and 21.3% (n = 10) for FM.
Other associated procedures were performed in 5.7% (n = 20) of all patients. The mean cardiopulmonary bypass time was 168 ± 49 min for MM and 178 ± 73 min for MF. The mean bypass time for FF was 158 ± 41 and 172 ± 54 min for FM. The mean aortic crossclamping time was as follows: 121 ± 29 min for MM, 123 ± 39 min for MF, 119 ± 33 min for FF and 126 ± 39 min for FM. During weaning from extracorporeal circulation, normal homograft function was confirmed via transoesophageal echocardiography.
The surgical profiles are summarized in Table 3 .
Follow-up
After discharge from hospital, patients attended appointments in our outpatient clinic at 6 and 12 months postoperatively, followed by annual routine examinations. Follow-up included transthoracic 
Statistics
The Mann-Whitney U-test was used to compare metric variables in two groups. Fisher's exact test was used to compare proportions in two groups. Kaplan-Meier curves were used to display time-to-event in several groups and the log-rank test was used to statistically assess differences between such curves. The proportional hazard hypothesis was checked using a test based on the scaled Schoenfeld residuals. Mortality rates were derived and Longitudinal analysis of stenosis and EF was conducted on the basis of linear mixed models with time, squared time, donor gender and their interaction as fixed effects and random intercept and random slope. The linear mixed models were fitted using the R function 'lme'. Longitudinal analysis of insufficiency was performed using the generalized linear mixed model with binarydependent variable with time, the predictor of interest and their interaction as fixed effects and a random intercept. The models were fitted by maximum likelihood and numerical integration via Gauss-Hermite quadrature using the R function glmmML from the package of the same name. Within the (generalized) linear mixed models, significance was assessed on the basis of the Wald test. P-values smaller than 0.05 were considered significant. All statistical analyses were performed with the statistical software R, version 2.14.
RESULTS
P-values were calculated separately for male and female recipients because of outcome differences for male and female patients in general.
Of the 350 patients, 193 were male recipients of male donors, 64 male recipients of female donors, 47 female recipients of female donors and 46 female recipients of male donors. The main indication for surgery was degenerative aortic valve disease.
There was no significant difference regarding age of female recipients, receiving homografts from either male or female donors (57 ± 10 years/55 ± 12 years, P = 0.65). In case of male recipients, there was also no statistical difference regarding age of patients receiving homografts from either male or female donors (52 ± 12 years/49 ± 13 years, P = 0.092).
Donor age did also not differ for gender-compatible and incompatible groups (47 ± 12 years for MM and 46 ± 12 years for MF, P = 0.75; 40 ± 15 years for FM, 42 ± 12 years for FF, P = 0.51).
The mean overall follow-up time was 8.1 and 7.5 years for FM, 8.9 years for FF, 8.1 years for MM and 7.7 years for MF.
Regarding other known variables possibly influencing patient outcome and homograft durability, gender-compatible and incompatible groups did not differ significantly (Tables 1-3) .
The overall mortality rate was 18.5% with the highest 10-year mortality for FM (25.3%) and the lowest mortality for FF (11.1%).
Survival of recipients of gender-incompatible homografts was not significantly different compared with recipients who received gender-compatible homografts (Fig. 1) . The hypothesis of proportional hazards was not rejected.
In total, 95 patients (27.1%) needed reoperation during followup. For these patients, the mean time to reoperation was 91.4 months. The main causes for reoperation were degeneration and infection of the homograft valve. For patients receiving gendercompatible homografts, the mean time to reoperation for MM was 86.5 months and for FF 108 months. In the MM group 57 patients (29.5%) and in the FF group 11 (23.9%) needed reoperation during follow-up.
For patients receiving gender-incompatible homografts, the mean time to reoperation for FM was 90.2 months and for MF 96.9 months. Eight patients of the FM group (17.0%) and 19 patients (29.7%) of the MF group needed reoperation. Event-free survival (i.e. survival without reoperation) of recipients of gender-incompatible homografts was not significantly different compared with recipients who received gender-compatible homografts (Fig. 2) . The hypothesis of proportional hazards was not rejected. Number of events during follow-up (death, reoperation, reoperation and/ or death) is presented in Table 1 for each group.
The effect of gender incompatibility on 'death' and 'death or reoperation' was also non-significant in multivariable Cox models for both male and female recipients after adjusting for a set of preselected variables known as possible risk factors: age, previous aortic valve replacement, diabetes mellitus, donor age, graft preservation (fresh wet/cryopreserved), graft ( pulmonary/aortic homograft in aortic position), allograft valve procedure (subcoronary mini-root implantation) (Supplementary material, Table S1 ).
Postoperative echocardiographic evaluation of the homograft valve showed a significantly higher postoperative gradient for the MF group compared with the MM group (Fig. 3) . Other parameters did not reach statistical significance (Figs 4 and 5) . However, according to the analyses based on the (generalized) linear mixed model, the evolution of echocardiographic performance of the homograft valve over time was not significantly worse in case of gender incompatibility than in case of gender compatibility. We could not identify any detrimental effect of gender mismatch on homograft durability.
DISCUSSION
The aortic homograft combines several advantages such as excellent haemodynamics, durability in case of native or prosthetic valve endocarditis and no need for long-term oral anticoagulation [11] . Compared with standard tissue and mechanical valves, the number of homograft implants is limited due to several factors: valve shortage (limited donor availability) [10] , more demanding implantation techniques compared with other devices [2] , and the need for establishing a homograft bank to reduce costs [12] . Several factors have been identified influencing homograft durability and patient outcome. Younger recipients carry a higher risk of homograft valve degeneration [2] . The mechanism of this finding is not clear; some authors assume an immunological basis, possibly related to a non-specific production of antibodies and a greater immune response with a higher rate of postoperative fever [13, 14] .
Older donor age also seems to have a detrimental effect on homograft durability [2] , due to age-related structural changes in the valve connective tissue and cellular components [15] .
The influence of gender mismatch on the outcome of patients receiving a homograft aortic valve is not yet clear. In heart transplantation, it can be shown that gender mismatch influences survival [6] . Especially male recipients of female donor hearts and female recipients of male donor hearts have an increased mortality compared with gender-matched recipients [16, 17] . Among many possible mechanisms like size mismatch [8] , it is thought that minor histocompatibility antigens located on Y-Chromosome and antibody development during pregnancy may cause higher incidence of rejection. Another explanation could be the different expression of human leucocyte antigens (HLA) in female patients and a different hormonal influence on the graft after transplantation [7, 17, 18] .
Cryopreserved homografts are considered to contain viable fibroblasts at the time of implantation [19] . O'Brien et al. were also able to detect persisting viable donor cells 9.2 years after implantation of a gender-mismatched cryopreserved allograft aortic valve [20] .
Antigenic valvular elements lead to a donor-specific humoral and cell-mediated immune response [21] . The clinical consequences of these findings are contradictory. In case of human leucocyte antigen compatibility, some authors link echocardiographic valve failure to HLA-DR-mismatched valves [14] ; others failed to show an influence of HLA incompatibility on valve performance [22] .
To what extent preserved viability and antigenicity in homograft valves influence patient outcome and valve durability is unclear. Assuming that preserved viability also leads to a preserved genderspecific antigen expression on implanted homograft valves, our aim was to investigate the influence of gender-mismatched aortic homografts on patient outcome.
We were not able to detect a significant difference between gender-mismatched and matched allografts regarding death, need for reoperation or echocardiographic allograft function during follow-up.
One reason for these findings might be that valve cellularity post implantation may be of host origin, due to ingrowth of host fibroblasts [23] . This may lead to the preserved leaflet cellularity and function of homograft valves. Another reason might be that freezing/thawing protocols and ischaemic time (time between donor death and cryopreservation of the donor valve) are also suspected to influence valve durability due to reduced cell viability and antigenicity [14, 19, 24, 25] .
One limitation of this study is its retrospective design with subsequent lack of control over the data quality and subsequent heterogeneity between the examined groups (although the groups did not differ statistically significantly for the variables analysed). Furthermore, additional immunohistochemical examination could help to determine the presence of viable cells in explanted valves. The group of female recipients was relatively small compared with the group of male recipients, making statistics less reliable: according to Freedman's method as implemented in the function 'powerCT' from the R package 'powerSurvEpi', the power to detect a hazard ratio of 2 as significant for gender incompatibility for the combined outcome (death or reoperation) based on the available sample sizes is 90% for male patients but only 46% for female patients. To detect a hazard ratio of 2 with a power of 80% for the female patients, a size of 107 for each group would be needed. The power of the study can thus be seen as moderate.
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